Matching articles for "Zepbound"
Issue 1754 · May 11, 2026 Free
In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss

The FDA has approved Wegovy HD , a 7.2-mg dose of the injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, for use in adults who have tolerated the 2.4-mg dose for at least 4 weeks and…

Med Lett Drugs Ther. 2026 May 11; 68(1754):77 doi:10.58347/tml.2026.1754c
The FDA has approved Wegovy HD , a 7.2-mg dose of the injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, for use in adults who have tolerated the 2.4-mg dose for at least 4 weeks and require additional weight reduction.
Issue 1748 · February 16, 2026 Free
In Brief: Removal of Suicidality Warning from GLP-1 Agonists for Weight Management

The FDA has requested the removal of the suicidal behavior and ideation warning from the labels of the 3 glucagon-like peptide-1 (GLP-1) receptor agonists approved for chronic weight management: liraglutide…

Med Lett Drugs Ther. 2026 Feb 16; 68(1748):32 doi:10.58347/tml.2026.1748e
The FDA has requested the removal of the suicidal behavior and ideation warning from the labels of the 3 glucagon-like peptide-1 (GLP-1) receptor agonists approved for chronic weight management: liraglutide (Saxenda) , semaglutide (Wegovy) , and tirzepatide (Zepbound) . The warning was initially included in the labels of these drugs based on an increased risk of suicidal behavior and ideation observed with older weight loss drugs.
Issue 1747 · February 2, 2026
Oral Semaglutide (Wegovy) for Weight Loss

The FDA has approved an oral tablet formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) for chronic weight management in adults. It is the first oral GLP-1 receptor agonist…

Med Lett Drugs Ther. 2026 Feb 2; 68(1747):17-8 doi:10.58347/tml.2026.1747a
The FDA has approved an oral tablet formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) for chronic weight management in adults. It is the first oral GLP-1 receptor agonist to be approved in the US for weight management. An injectable formulation of Wegovy was approved for the same indication in 2021.1 The injectable GLP-1 receptor agonist liraglutide ( Saxenda , and generic) and the injectable glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Zepbound) are also FDA-approved for chronic weight management (see Table 1).
Issue 1739 · October 13, 2025
Semaglutide (Wegovy) for MASH

The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has received accelerated approval from the FDA for treatment of noncirrhotic metabolic dysfunction-associated…

Med Lett Drugs Ther. 2025 Oct 13; 67(1739):161-2 doi:10.58347/tml.2025.1739a
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has received accelerated approval from the FDA for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH; previously known as nonalcoholic steatohepatitis [NASH]) with moderate to advanced liver fibrosis in adults. It is the second drug and the first GLP-1 receptor agonist to be approved in the US for treatment of MASH; resmetirom (Rezdiffra) , a thyroid hormone receptor-beta agonist, was granted accelerated approval for the same indication in 2024.
Issue 1734 · August 4, 2025
Drugs and Devices for Weight Management

Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m 2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI,…

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):121-8 doi:10.58347/tml.2025.1734a
Overweight is generally defined as a body mass index (BMI) between 25 and 29.9 kg/m 2 in adults. A BMI ≥30 is considered obese (criteria differ slightly in Asian patients). In patients with an elevated BMI, a 5-10% reduction in weight has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the traditional methods for losing weight, but they are often inadequate; the American College of Cardiology no longer recommends that all patients try lifestyle modification alone before adding pharmacologic treatment for weight loss. Guidelines on pharmacologic treatment of obesity from the American Gastroenterological Association (AGA) were last updated in 2022.
Issue 1734 · August 4, 2025
Comparison Table: Some Drugs for Weight Management (online only)

View the Comparison Table: Some Drugs for Weight Management

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e127-30 doi:10.58347/tml.2025.1734b
View the Comparison Table: Some Drugs for Weight Management
Issue 1729 · May 26, 2025
Drugs for Chronic Heart Failure

Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF…

Med Lett Drugs Ther. 2025 May 26; 67(1729):81-8 doi:10.58347/tml.2025.1729a
Pharmacologic management of chronic heart failure (HF) is primarily determined by the patient's left ventricular ejection fraction (LVEF) and severity of symptoms. Patients with chronic HF who have an LVEF ≤40% are considered to have heart failure with reduced ejection fraction (HFrEF) and those with an LVEF ≥50% are considered to have heart failure with preserved ejection fraction (HFpEF). Patients with an LVEF of 41-49% have heart failure with mildly reduced or mid-range ejection fraction.
Issue 1722 · February 17, 2025
Tirzepatide (Zepbound) for Obstructive Sleep Apnea

The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide (Zepbound) has been approved by the FDA for treatment of moderate to severe…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):29-31 doi:10.58347/tml.2025.1722c
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide (Zepbound) has been approved by the FDA for treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is the first drug to be approved in the US for this indication. Zepbound is also approved for chronic weight management in adults with obesity and in those who are overweight and have at least one weightrelated comorbidity. Tirzepatide is also available as Mounjaro for treatment of type 2 diabetes.
Issue 1718 · December 23, 2024 Free
In Brief: New FDA Warning of Pulmonary Aspiration with GLP-1 Receptor Agonists

The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity) , exenatide (Byetta, Bydureon BCise) , liraglutide (Saxenda, Victoza) , and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual…

Med Lett Drugs Ther. 2024 Dec 23; 66(1718):201-2 doi:10.58347/tml.2024.1718a
The package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity) , exenatide (Byetta, Bydureon BCise) , liraglutide (Saxenda, Victoza) , and semaglutide (Ozempic, Rybelsus, Wegovy) and the dual glucosedependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) have been updated to include rare postmarketing reports of pulmonary aspiration associated with their use in patients undergoing elective surgery or other procedures requiring general anesthesia or deep sedation who had residual gastric contents despite preoperative fasting.
Issue 1708 · August 5, 2024 Free
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)

View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):e1-2 doi:10.58347/tml.2024.1708d
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Issue 1692 · December 25, 2023
Tirzepatide (Zepbound) for Chronic Weight Management

The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, which was approved by the FDA as Mounjaro for treatment of type 2 diabetes in…

Med Lett Drugs Ther. 2023 Dec 25; 65(1692):205-7 doi:10.58347/tml.2023.1692c
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, which was approved by the FDA as Mounjaro for treatment of type 2 diabetes in 2022, has now been approved as Zepbound (Lilly) for chronic weight management in adults who have a BMI ≥30 kg/m 2 or a BMI ≥27 kg/m 2 and at least one weight-related comorbidity. The injectable GLP-1 receptor agonists liraglutide (Saxenda) and semaglutide (Wegovy) are approved for chronic weight management in patients ≥12 years old.
Issue 1690 · November 27, 2023 Free
In Brief: GI Effects of GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2…

Med Lett Drugs Ther. 2023 Nov 27; 65(1690):191-2 doi:10.58347/tml.2023.1690e
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes and weight management (see Table 1), but they delay gastric emptying and commonly cause nausea and vomiting. Gastroparesis and bowel obstruction (ileus) have also been reported with their use.